Saturday, August 30, 2008
pehel.com
Home Latest News Pakistan World Science / Technology Sports Entertainment Health Business


Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration
Source: Medical News Today E-Mail this News Story to a friend E-Mail this Story
Category: Health
Publication Date: Fri, 09 May 2008 00:00:00 PDT
News URL: http://www.medicalnewstoday.com/articles/106850.php
Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular DegenerationBayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the first patient has been dosed in the VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of Age-related Macular Degeneration (wet AMD), a leading cause of blindness in adults.
Click here for full Story
http://www.medicalnewstoday.com/articles/106850.php
Bookmark this news story online:
Add Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to BlinkListAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to DeliciousAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to DiggAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to FarkAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to FurlAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to BlogarithmAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to MeneameAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to My Yahoo!Add Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to ReddItAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to ShadowsAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to SimpyAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to SpurlAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to Sync2ItAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to MagnoliaAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to NewsVineAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to Ask Jeeves
Add Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to Raw SugarAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to DiigoAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to NetVouzAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to Stumble UponAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to SegnaloAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to Google BookmarksAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to Microsoft LiveAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to BlogMarksAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to WinkAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to TechnoratiAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to Feed Me LinksAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to LinkaGoGoAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to BlueDotAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to Mister WongAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to TailRankAdd Bayer And Regeneron Dose First Patient In Second Phase 3 Study For VEGF Trap-Eye In Wet Age-Related Macular Degeneration to Yahoo Bookmarks

Comments

No comments found... be the first one to comment on this story :)

Post a Comment
Name:
   
E-Mail Address:
   
Website / Blog URL (optional):
   
Comments:
   
Security Code:
   
  
   By submitting these comments, you are agreeing to our Terms of Service
    
Latest News
Latest News World News Pakistan News Technology News Entertainment News Business News Sports News
bullet Repair Stem Cell Institute Says Stanford University's Stem Cell Study Confirms The Futility Of Embryonics In Human Therapy
bullet Pediatric Heart Transplants At Montefiore Approved By NY State Department Of Health
bullet By Altering Hundreds Of Genes, Black Raspberries Slow Cancer
bullet Orthopaedic Surgeons Play Key Role In Stroke Recovery
bullet Digital Pathology Leader Adds Third FDA Clearance For Digital Pathology In Breast Cancer
bullet Heart Risk Due To Low Radiation Doses Worth Investigating Say Scientists
bullet Magnesium Sulphate May Reduce Cerebral Palsy
bullet Catheter Procedures Guided By Tiny 3-D Ultrasound Probe
bullet Doctors Concerned About Risk Of Repeat Attacks In Heart Patients
bullet Jumping For Joy ... And Stronger Bones
bullet UT Southwestern Researchers Find Antidepressants Need New Nerve Cells To Be Effective
bullet Guideline On Diagnosis And Treatment Of Primary Aldosteronism Released By Endocrine Society
bullet American Diabetes Wholesale Announces 2008 Diabetes Educator Of The Year Contest
bullet Morphotek(R), Inc. Expands Its Phase II Trial Site Selections In The European Union - Pancreatic Cancer Treatment
bullet Cook Medical Announces Rapid Adoption Of Its Breakthrough EVOLUTION(R) Device Designed To Remove Faulty Pacemaker Leads
bullet New Therapies Increasingly Being Used To Treat Liver Cancer
bullet MarkMonitor Reports Continuing Rise In Online Abuse Of Top Drug Brands
bullet Cancer - Curis Announces Dosing Of First Patient In Phase I Clinical Trial Of CUDC-101
bullet Class Of Diabetes Drugs Carries Significant Cardiovascular Risks
bullet Randomized Phase 2 Study Of IMC-A12 And IMC-1121B For Advanced Prostate Cancer Commences Patient Enrollment
bullet Experimental Therapy May Lead To Macular Degeneration
bullet Interventional Ophthalmology Procedure Indicated For Treatment Of Glaucoma
bullet ADAGIO Trial Results Show Teva's AZILECT(R) 1 Mg Tablets Slow Progression Of Parkinson's Disease
bullet Immigrants From India, Pakistan Face U.S. Prostate, Breast Cancer Risks
bullet Even Without Dementia, Mental Skills Decline Years Before Death
 
© 2007 Verge Systems